Advances in the treatment of graft-versus-host disease.
Graft-versus-host disease (GVHD) is a complicated disease whose treatment requires an equally multifaceted approach. Recipient conditioning, donor T cell activation, and end stage effectors all may be potential targets for treatment. Many drugs used in the past are returning to the forefront for investigation. Some of the newer nucleoside analogs that are in various stages of development, such as fludarabine and pentostatin, are showing promising activity in GVHD.
Vogelsang
G B
GB
Johns Hopkins University, Baltimore, MD 21287, USA.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D016207:Cytokines / Q000502:physiology; D006086:Graft vs Host Disease / Q000517:prevention & control / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D017370:Interleukin-11 / Q000494:pharmacology / Q000627:therapeutic use; D007422:Intestines / Q000187:drug effects / Q000528:radiation effects; D017708:Leukocyte Transfusion; D008213:Lymphocyte Activation / Q000187:drug effects; D011837:Radiation-Protective Agents / Q000494:pharmacology / Q000627:therapeutic use; D020123:Sirolimus / Q000627:therapeutic use; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D018417:Th1 Cells / Q000187:drug effects; D018418:Th2 Cells / Q000187:drug effects; D014019:Tissue Donors; D019172:Transplantation Conditioning / Q000009:adverse effects; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000502:physiology
D000911:Antibodies, Monoclonal; D016207:Cytokines; D007166:Immunosuppressive Agents; D017370:Interleukin-11; D011837:Radiation-Protective Agents; D014409:Tumor Necrosis Factor-alpha; D020123:Sirolimus